178 related articles for article (PubMed ID: 26608877)
1. An integrated assessment of morphology, size, and complement activation of the PEGylated liposomal doxorubicin products Doxil®, Caelyx®, DOXOrubicin, and SinaDoxosome.
Wibroe PP; Ahmadvand D; Oghabian MA; Yaghmur A; Moghimi SM
J Control Release; 2016 Jan; 221():1-8. PubMed ID: 26608877
[TBL] [Abstract][Full Text] [Related]
2. Flow cytometric analysis of supravesicular structures in doxorubicin-containing pegylated liposomes.
Milosevits G; Rozsnyay Z; Kozma GT; Milosevits J; Tömöry G; Robotka H; Rosivall L; Szebeni J
Chem Phys Lipids; 2012 May; 165(4):482-7. PubMed ID: 22206709
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Physicochemical Properties of Generic Doxorubicin HCl Liposome Injection with the Reference Listed Drug.
Maiti K; Bhowmick S; Jain P; Zope M; Doshi K; Rajamannar T
Anticancer Agents Med Chem; 2018; 18(4):597-609. PubMed ID: 29173186
[TBL] [Abstract][Full Text] [Related]
4. Effect of the concentration process on unloaded and doxorubicin loaded liposomal dispersions.
Perinelli DR; Cespi M; Rendina F; Bonacucina G; Palmieri GF
Int J Pharm; 2019 Apr; 560():385-393. PubMed ID: 30802548
[TBL] [Abstract][Full Text] [Related]
5. Practical aspects in size and morphology characterization of drug-loaded nano-liposomes.
Peretz Damari S; Shamrakov D; Varenik M; Koren E; Nativ-Roth E; Barenholz Y; Regev O
Int J Pharm; 2018 Aug; 547(1-2):648-655. PubMed ID: 29913218
[TBL] [Abstract][Full Text] [Related]
6. Accelerated blood clearance of PEGylated liposomes upon repeated injections: effect of doxorubicin-encapsulation and high-dose first injection.
Ishida T; Atobe K; Wang X; Kiwada H
J Control Release; 2006 Oct; 115(3):251-8. PubMed ID: 17045355
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo characterizations of PEGylated liposomal doxorubicin.
Jiang W; Lionberger R; Yu LX
Bioanalysis; 2011 Feb; 3(3):333-44. PubMed ID: 21320053
[TBL] [Abstract][Full Text] [Related]
8. The Comparison of Biodistribution, Efficacy and Toxicity of Two PEGylated Liposomal Doxorubicin Formulations in Mice Bearing C-26 Colon Carcinoma: a Preclinical Study.
Razavi-Azarkhiavi K; Jafarian AH; Abnous K; Razavi BM; Shirani K; Zeinali M; Jaafari MR; Karimi G
Drug Res (Stuttg); 2016 Jun; 66(6):330-6. PubMed ID: 27022719
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics, efficacy and toxicity of different pegylated liposomal doxorubicin formulations in preclinical models: is a conventional bioequivalence approach sufficient to ensure therapeutic equivalence of pegylated liposomal doxorubicin products?
Mamidi RN; Weng S; Stellar S; Wang C; Yu N; Huang T; Tonelli AP; Kelley MF; Angiuoli A; Fung MC
Cancer Chemother Pharmacol; 2010 Nov; 66(6):1173-84. PubMed ID: 20661737
[TBL] [Abstract][Full Text] [Related]
10. Rapid scale-up and production of active-loaded PEGylated liposomes.
Roces CB; Port EC; Daskalakis NN; Watts JA; Aylott JW; Halbert GW; Perrie Y
Int J Pharm; 2020 Aug; 586():119566. PubMed ID: 32622812
[TBL] [Abstract][Full Text] [Related]
11. Prevention of infusion reactions to PEGylated liposomal doxorubicin via tachyphylaxis induction by placebo vesicles: a porcine model.
Szebeni J; Bedőcs P; Urbanics R; Bünger R; Rosivall L; Tóth M; Barenholz Y
J Control Release; 2012 Jun; 160(2):382-7. PubMed ID: 22421426
[TBL] [Abstract][Full Text] [Related]
12. Enhanced doxorubicin delivery to the brain administered through glutathione PEGylated liposomal doxorubicin (2B3-101) as compared with generic Caelyx,(®)/Doxil(®)--a cerebral open flow microperfusion pilot study.
Birngruber T; Raml R; Gladdines W; Gatschelhofer C; Gander E; Ghosh A; Kroath T; Gaillard PJ; Pieber TR; Sinner F
J Pharm Sci; 2014 Jul; 103(7):1945-1948. PubMed ID: 24801480
[TBL] [Abstract][Full Text] [Related]
13. Using solution X-ray scattering to determine the high-resolution structure and morphology of PEGylated liposomal doxorubicin nanodrugs.
Schilt Y; Berman T; Wei X; Barenholz Y; Raviv U
Biochim Biophys Acta; 2016 Jan; 1860(1 Pt A):108-19. PubMed ID: 26391840
[TBL] [Abstract][Full Text] [Related]
14. Development of a Flow-Through USP-4 Apparatus Drug Release Assay to Evaluate Doxorubicin Liposomes.
Yuan W; Kuai R; Dai Z; Yuan Y; Zheng N; Jiang W; Noble C; Hayes M; Szoka FC; Schwendeman A
AAPS J; 2017 Jan; 19(1):150-160. PubMed ID: 27485642
[TBL] [Abstract][Full Text] [Related]
15. Pegylated liposomal doxorubicin in ovarian cancer.
Green AE; Rose PG
Int J Nanomedicine; 2006; 1(3):229-39. PubMed ID: 17717964
[TBL] [Abstract][Full Text] [Related]
16. Variability of Complement Response toward Preclinical and Clinical Nanocarriers in the General Population.
Benasutti H; Wang G; Vu VP; Scheinman R; Groman E; Saba L; Simberg D
Bioconjug Chem; 2017 Nov; 28(11):2747-2755. PubMed ID: 29090582
[TBL] [Abstract][Full Text] [Related]
17. Size Determination of a Liposomal Drug by Small-Angle X-ray Scattering Using Continuous Contrast Variation.
Garcia-Diez R; Gollwitzer C; Krumrey M; Varga Z
Langmuir; 2016 Jan; 32(3):772-8. PubMed ID: 26673729
[TBL] [Abstract][Full Text] [Related]
18. Accelerated blood clearance of PEGylated liposomes containing doxorubicin upon repeated administration to dogs.
Suzuki T; Ichihara M; Hyodo K; Yamamoto E; Ishida T; Kiwada H; Ishihara H; Kikuchi H
Int J Pharm; 2012 Oct; 436(1-2):636-43. PubMed ID: 22850293
[TBL] [Abstract][Full Text] [Related]
19. Liposomal doxorubicin for active targeting: surface modification of the nanocarrier evaluated in vitro and in vivo: challenges and prospects.
Jakoby J; Beuschlein F; Mentz S; Hantel C; Süss R
Oncotarget; 2015 Dec; 6(41):43698-711. PubMed ID: 26497207
[TBL] [Abstract][Full Text] [Related]
20. Liposomal doxorubicin: the good, the bad and the not-so-ugly.
Szebeni J; Fülöp T; Dézsi L; Metselaar B; Storm G
J Drug Target; 2016 Nov; 24(9):765-767. PubMed ID: 27030293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
